Gilead Sciences, Inc.GILDNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank79
3Y CAGR-1.4%
5Y CAGR-3.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-1.4%/yr
vs +15.7%/yr prior
5Y CAGR
-3.1%/yr
Consistent
Acceleration
-17.1pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $13.71B | -34.2% |
| 2024 | $20.84B | +60.2% |
| 2023 | $13.01B | -9.0% |
| 2022 | $14.29B | +32.5% |
| 2021 | $10.79B | -32.8% |
| 2020 | $16.05B | +90.2% |
| 2019 | $8.44B | +5.8% |
| 2018 | $7.98B | +4.8% |
| 2017 | $7.61B | -10.4% |
| 2016 | $8.50B | - |